|
[Objective]: coronary intervention has become the primary means of treatment of coronary heart disease, the Beijing Union Medical College Hospital, has not yet reported long-term follow-up results of these patients, the study Recalling the single-center coronary intervention in patients with long-term follow-up results, in order to evaluate coronary involved in the safety and efficacy of the treatment. [Materials and Methods]: 2096 cases of income of the Beijing Union Medical College Hospital from January 2003 to December 2007 hospitalized patients all underwent coronary interventional treatment excluded patients with incomplete clinical data of 2053 patients will be included in the scope of the study, outpatient clinical outcomes of 1945 patients followed up or in the form of telephone follow-up data, the establishment of a database for statistical analysis using SPSS software. [Results]: the age of the 1945 patients enrolled was 63.69 ± 11.19 years, 1366 cases of male patients, of which 615 cases of acute ST-segment elevation myocardial infarction patients (31.6%) patients with unstable angina and non-ST-segment elevation myocardial infarction 795 cases (40.9%), 535 cases of unstable angina patients (27.5%); 98.1% of the patients had at least had a risk factor; coronary angiography showed three lesions in 760 patients (39.1%), double vessel disease in patients 613 cases (31.5%), with single vessel disease in 572 cases (29.4%); All patients were implanted stent 3492 per patient on average 1.79 stent implantation, the implanted stent diameter 3.01 ± 0.4mm, stent implantation length of 21.99 ± 7.2mm, where drug-eluting stents, and 2445 (70.1%), 1047 bare metal stents, drug-eluting stent use proportion gradually increased from 25.9% in 2003 to 86.2% in 2007; drugs eluting stents in stable angina proportion of patients in the use of up to 82.6%, while the proportion of bare metal stents in ST short-elevation myocardial infarction patients up to 49%; average length of stay for all patients was 10.35 ± 8.33 days, the total cost is RMB 70878 ± 35440 devices spend RMB 55745 ± 39398; 99.9% of patients during hospitalization dual antiplatelet drugs, and other coronary secondary prevention drugs also regulate the use of. All patients with follow-up time was 34.98 ± 19.63 months (1-83 months), 268 cases (13.8%) to reach the endpoint of the study include: all-cause mortality in 135 patients (6.9%), center endogenous cause death in 87 cases (4.5% including 22 patients died of infectious diseases, 19 patients died of cancer), non-cardiac death, other causes of seven cases; stent thrombosis in 42 cases (2.16%); 459 cases (23.6%) patients repeat coronary angiography or underwent coronary CTA, 129 cases (6.6%) patients with in-stent restenosis (86 cases (8.2%) patients with bare metal stent restenosis in 43 cases (1.8%) patients with drug-eluting stent restenosis) ; 123 patients in the follow-up period, vascular line of target lesion revascularization therapy (6.3%); the recurrence of myocardial infarction (4.4%) of 86 patients in the follow-up period, 63 cases of non-fatal myocardial infarction; compare ST-segment elevation myocardial infarction in patients with non-ST-segment elevation myocardial infarction \\ unstable angina patients with stable angina patients during follow-up mortality, cardiac mortality, reinfarction rate, target lesion revascularization treatment rate of stent thrombosis the chances were: 9.3% vs6.7vs4.8% (p = 0.011), 8.1% vs3.3% vs2.0% (p = 0.000), 6.3% vs4.4% vs2.2% (p = 0.003) interventional treatment of patients with stable coronary artery disease, 7.8% vs6.9% vs3.7% (p = 0.012), 4.3% vs2.0% vs0.5% (p = 0.001), the event rate was significantly higher than the other types of patients with coronary heart disease; compare bare metal stent implantation alone, separate drug-eluting stents, implantation of bare metal and drug-eluting stents in patients with cumulative death, cardiac death, target lesion revascularization, stent thrombosis probability were: 13.1% vs 4.1% vs5.5% (p = 0.000), 9.7% vs2.05% vs3.4% (p = 0.000), 9.2% vs3.7% vs16.4% (p = 0.000), 2.04% vsl.96% vs3.42% (p = 0.506), the event rate after implantation of drug-eluting stents was significantly lower than the bare metal stent implantation; calculation the bare metal stents prevention stent restenosis in different years the cost-effectiveness ratio of 35705-50933 yuan / person, and drug-eluting stents prevention stent restenosis in the use of different years cost-effectiveness ratio of 51808-58421 yuan / person; stent thrombosis after long-term use of Plavix prevention formation The analysis showed that: the cost-effectiveness of bare metal stents than 5068 yuan / person, drug-eluting stents cost-effectiveness ratio of 10,813 yuan / person. [Conclusion]: the probability of patients with acute coronary syndrome in the interventional treatment of cardiovascular events was significantly higher than in patients with stable angina pectoris, implantation of drug-eluting stents compared to bare metal stent implantation can significantly reduce patients of cardiovascular events chance, and no significant increase in the probability of stent thrombosis; the cost of drug-eluting stents than bare metal stents, drug-eluting stents to prevent in-stent restenosis and stent thrombosis cost-effectiveness ratio is also higher than bare metal stents.
|